Durvalumab
- Generic Name
- Durvalumab
- Brand Names
- Imfinzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1428935-60-7
- Unique Ingredient Identifier
- 28X28X9OKV
- Background
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tum...
- Indication
Durvalumab is indicated for the treatment of adults with the following conditions:
- Associated Conditions
- Extensive-stage Small Cell Lung Cancer (SCLC), Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer, Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Stage III Non-small Cell Lung Cancer, Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC)
- Associated Therapies
- First Line Chemotherapy
Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma
- First Posted Date
- 2017-02-15
- Last Posted Date
- 2017-02-16
- Lead Sponsor
- Singapore General Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT03054532
- Locations
- 🇸🇬
Raffles Hospital Singapore, Singapore, Singapore
🇸🇬National University Hospital Singapore, Singapore, Singapore
🇸🇬Singapore General Hospital, Singapore, Singapore
Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-02-08
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 31
- Registration Number
- NCT03046862
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
- Conditions
- Interventions
- First Posted Date
- 2017-02-06
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 987
- Registration Number
- NCT03043872
- Locations
- 🇺🇦
Research Site, Zaporizhzhia, Ukraine
A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection
- First Posted Date
- 2017-01-31
- Last Posted Date
- 2020-09-14
- Lead Sponsor
- University of Colorado, Denver
- Registration Number
- NCT03038477
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2023-03-14
- Target Recruit Count
- 50
- Registration Number
- NCT03030131
- Locations
- 🇫🇷
Amiens - Clinique de l'Europe, Amiens, France
🇫🇷Bayonne - CH, Bayonne, France
🇫🇷Le Mans - CHG, Le Mans, France
Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Recurrent Ovarian CarcinomaRefractory Ovarian CarcinomaPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaRefractory Fallopian Tube CarcinomaRefractory Primary Peritoneal Carcinoma
- Interventions
- First Posted Date
- 2017-01-20
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT03026062
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2017-01-12
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 13
- Registration Number
- NCT03019003
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
- First Posted Date
- 2017-01-09
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT03015129
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
- Conditions
- Refractory Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Mycosis FungoidesRecurrent Mature T- and NK-Cell Non-Hodgkin LymphomaRefractory Mycosis FungoidesRefractory Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedSezary SyndromeFolliculotropic Mycosis FungoidesRecurrent Cutaneous T-Cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 38
- Registration Number
- NCT03011814
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2017-01-02
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 33
- Registration Number
- NCT03007407
- Locations
- 🇺🇸
St. Joseph Mercy-Canton, Canton, Michigan, United States
🇺🇸Centralia Oncology Clinic, Centralia, Illinois, United States
🇺🇸UF Health Davis Cancer Pavilion and Shands Med Plaza, Gainesville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.